MedTrace Logo

Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav

NCT00519753 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 522

Last updated 2016-11-18

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.

Conditions

Interventions

DRUG

Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)

One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Mark C Jasek · Alcon Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519753 on ClinicalTrials.gov